Benzinga | May 5, 2021 07:33AM EDT

Kala Pharmaceuticals Q1 EPS $(0.49) Beats $(0.68) Estimate, Sales $3.30M Miss $4.18M Estimate

Kala Pharmaceuticals (NASDAQ:KALA) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.68) by 27.94 percent. This is a 9.26 percent increase over losses of $(0.54) per share from the same period last year. The company reported quarterly sales of $3.30 million which missed the analyst consensus estimate of $4.18 million by 21.05 percent. This is a 208.12 percent increase over sales of $1.07 million the same period last year.